Plexus director Karen Rapp sells $120,435 in PLXS shares

Plexus shares have surged 75% over the past year, but trade above InvestingPro fair value (P/E 35.2; market cap $6.4B) as an insider sells. Plexus reported fiscal Q3 non-GAAP EPS of $2.32 vs $2.13 expected and revenue of $1.3B vs $1.23B expected, citing record revenue, strong demand, and improved working-capital management. The company also raised its growth outlook for continued momentum into fiscal 2027, even as a director sold 500 shares at $240.87 under a Rule 10b5-1 plan.

Analysis

The insider sale is low-signal because it was pre-programmed, so the real issue is not governance but valuation versus durability. After a 75% run, PLXS is being priced like a mid-teens growth compounder, yet the business still looks like a cyclical manufacturing platform where any deceleration in bookings or mix can compress the multiple faster than EPS grows.

The beat/raise matters more for quality than for near-term upside: better working-capital discipline should support cash conversion over the next 2-4 quarters, but that is usually already rewarded in the stock once the market re-rates the name. The second-order effect is relative-value pressure across EMS: if investors decide this is the high-quality benchmark, cheaper names like JBL, CLS, and SANM can screen better on the same demand backdrop, especially if they have less valuation risk.

Contrarian view: consensus is likely underestimating how much of the move has been multiple expansion rather than fundamentals. If FY27 growth guidance merely confirms rather than accelerates, the stock can stall even with clean execution; the thesis breaks if revenue growth stays above the current re-rating threshold and margins continue to expand sequentially for another 1-2 quarters.

Key Decisions for Investors

• Pair trade: short PLXS / long CLS or JBL over the next 1-3 months; thesis is valuation normalization, not business deterioration. Target a 10-15% relative underperformance in PLXS if the next print is merely in-line.
• Do not read the 10b5-1 sale as a bearish catalyst. Treat it as noise unless additional insider selling shows up outside pre-arranged plans; otherwise, no standalone trade.
• Set an alert on PLXS for any downward revision to FY27 growth or gross margin guidance. A single guide cut or sequential deceleration would likely trigger a 3-5 turn multiple compression.
• If PLXS weakens but holds above the post-earnings breakout level for 2-3 weeks, avoid forcing a short; the market may still be paying for quality execution and cash conversion.
• Watch for rotation into cheaper EMS peers on any sector pullback; if industrial/medical demand remains firm, relative-value longs in CLS or JBL offer cleaner risk/reward than chasing PLXS at a premium multiple.